Neurocrine Biosciences Reports Second Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Neurocrine Bio. (NBIX) PT Raised to $145 at Piper Sandler Due to Ingrezza Long-Term Potential
August 4, 2020 9:10 AM EDTPiper Sandler analyst David Amsellem raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $145.00 (from $141.00) while maintaining an Overweight rating, citing Ingrezza sales and volumes, a cinrecerfront Phase III study in CAH patients, an increasingly deep pipeline, and the low rates of TD... More
Neurocrine Biosciences (NBIX) Tops Q2 EPS by 69c, Revenues Beat
August 3, 2020 4:42 PM EDTNeurocrine Biosciences (NASDAQ: NBIX) reported Q2 EPS of $1.42, $0.69 better than the analyst estimate of $0.73. Revenue for the quarter came in at $302.4 million versus the consensus estimate of $260.52 million.
"I want to thank healthcare providers and our employees for the perseverance they showed... More
